Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Pediatric Asthma Treatment Industry?

The market for pediatric asthma treatment has witnessed robust growth in recent times. The market, valued at $11.03 billion in 2024, is predicted to scale to $11.65 billion in 2025, with a compound annual growth rate (CAGR) of 5.6%. The growth observed in the historical period is associated with the increased prevalence of asthma in children, expanded consciousness about respiratory problems in young children, rising levels of air pollution and environmental allergens, increased health spending on child healthcare, and awareness drives conducted by NGOs and healthcare institutions regarding asthma.

In the forthcoming years, the pediatric asthma treatment market is projected to experience significant growth, reaching $14.39 billion in 2029, with a compound annual growth rate (CAGR) of 5.4%. The expansion during the forecast period can be credited to factors such as the rising incidence of allergic disorders in children, the growth of biologic therapies for severe pediatric asthma, the upsurge in investments in pediatric drug development, the heightened focus on personalized and precision medicine, and the increase in the middle-class population that has access to private healthcare. Key trends during the forecast period involve the advancement of pediatric-friendly biologic therapies, the creation of swift allergen identification tools, the incorporation of electronic health records, innovation in inhaler formulations, and breakthroughs in asthma immunotherapy.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25868&type=smp

#Which Factors Are Currently Driving The Growth Of The Pediatric Asthma Treatment Market?

The pediatric asthma treatment market is predicted to be boosted by the escalating prevalence of respiratory infections. These infections, which impact the respiratory tract including the nose, throat, airways, and lungs, are typically caused by pathogens such as viruses or bacteria. The heightened incidence of these infections is predominantly tied to increasing levels of air pollution. Pollutants like particulate matter and nitrogen dioxide undermine the respiratory system and increase the likelihood of infections. Pediatric asthma treatment is designed to diminish the regularity and severity of these respiratory infections by enhancing airway function and reducing inflammation, thereby decreasing susceptibility to infectious triggers. As per the Australian Institute of Health and Welfare, a government agency of Australia, chronic obstructive pulmonary disease was responsible for 3.6% of the entire disease burden in June 2024 and represented half of the total respiratory condition burden in 2023. Furthermore, it was estimated that about 638,000 people, or 2.5% of the Australian population, were suffering from chronic obstructive pulmonary disease in 2022. Consequently, the augmenting prevalence of respiratory infections is propelling the growth of the pediatric asthma treatment market.

How Is The Global Pediatric Asthma Treatment Market Structured In Terms Of Segments?

The pediatric asthma treatment market covered in this report is segmented –

1) By Type: Long-Term Control Medications, Quick-Relief Medications, Other Types

2) By Drug Class: Inhaled Corticosteroids, Long-Acting Beta Agonists, Leukotriene Modifiers, Antihistamines, Biologics

3) By Route Of Administration: Oral Route, Nasal Route, Injectable Route

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals, Clinics, Home Care, Other End users

Subsegments:

1) By Long-Term Control Medications: Inhaled Corticosteroids, Leukotriene Modifiers, Long-Acting Beta Agonists, Combination Inhalers, Biologic Therapies

2) By Quick-Relief Medications: Short-Acting Beta Agonists, Anticholinergics, Systemic Corticosteroids

3) By Other Types: Immunotherapy, Methylxanthines, Alternative Therapies

What Notable Trends Are Shaping The Direction Of The Pediatric Asthma Treatment Market?

Firms at the forefront of the pediatric asthma treatment industry are emphasizing the development of novel therapies, such as monoclonal antibodies, aiming to tackle and diminish airway inflammation in children. These monoclonal antibodies are man-made proteins crafted to imitate the immune system’s function to ward off damaging pathogens by selectively pinpointing certain cells or substances. For example, in April 2024, the U.S. Food and Drug Administration accorded approval to AstraZeneca PLC, a biotech and pharmaceutical organization based in the UK, for FASENRA (benralizumab), to be used as supplementary maintenance cure for severe asthma in children from 6 to 11 years, particularly with an eosinophilic phenotype. This antibody has been devised to limit asthma flare-ups and enhance symptom management by concentrating on and doing away with eosinophils. Fasenra is delivered through subcutaneous injection, initially every 4 weeks for the first three doses and subsequently every 8 weeks, with the dosing for children modified as per body weight.

Who Are The Main Participants Shaping The Pediatric Asthma Treatment Market Landscape?

Major companies operating in the pediatric asthma treatment market are Pfizer Inc., Merck And Co Inc., Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Limited, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Genentech Inc., Chiesi Farmaceutici S.p.A, Dr. Reddy’s Laboratories Ltd, Cipla Ltd, Lupin Limited, Zydus Lifesciences Ltd., ECU Health.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pediatric-asthma-treatment-global-market-report

Which Region Currently Holds The Largest Share In The Pediatric Asthma Treatment Market?

North America was the largest region in the pediatric asthma treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pediatric asthma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=25868&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model